Olaparib Continuous (28-Day cycle) 300 mg BD.
D5336C00001
Phase 2 small_molecule active
Quick answer
Olaparib Continuous (28-Day cycle) 300 mg BD. for Metastatic Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Metastatic Triple Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active